Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Multiple Sclerosis

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

Eur J Neurol.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Menoyo JLS, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group

doi: 10.1111/ene.13824.

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

JAMA Neurol.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

doi: 10.1001/

Multiple Sclerosis

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

JAMA Neurol.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T

doi: 10.1001/jamaneurol.

Multiple Sclerosis

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Lancet Neurol

Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL

doi: 10.1016/S1474-4422(20)30342-2

RECOMMENDED

Aging and Cognitive FunctionsMultiple Sclerosis

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis

Brain.

Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O

doi: 10.1093/brain/awz156.

Multiple Sclerosis

Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study

J Neurol Neurosurg Psychiatry.

Crielaard L, Kavaliunas A, Ramanujam R, Olsson T, Hillert J, Stridh P, Kockum I, Manouchehrinia A

doi: 10.1136/jnnp-2018-319913.

Multiple Sclerosis

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Ann Neurol.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L

doi: 10.1002/ana.25313.

Multiple Sclerosis

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

JAMA Neurol.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T, MSBase Study Group

doi: 10.1001/jamaneurol.

Related content

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis

Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis